Approval from the FDA means that J&J’s Janssen unit has stolen a march on its rivals who are also developing drugs for this niche - Pfizer/Astellas with Xtandi (enzalutamide), Bayer/Orion’s ...

Q4 2024 Earnings Call Transcript March 27, 2025 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is ...

Pfizer and Astellas’ Xtandi has shown it is effective in men with prostate cancer that has spread but has not yet become hormone resistant, stepping up pressure on rival therapy Zytiga from ...

Monte Rosa Therapeutics’ plan to develop a molecular glue degrader in a wide range of cancers has come unstuck. | Monte Rosa ...

Astellas Pharma Inc. has a diverse pipeline ... supported by strong sales of enzalutamide and faster-than-expected zolbetuximab market penetration. Operational expenses have increased due to ...

Astellas is a multi-billion-dollar company that sells the enzalutamide product, Xtandi, in South Africa. According to the 15-page judgment by AJ Le Grange, the following order was made as the ...

Astellas is a multi-billion-dollar company that sells the enzalutamide product, Xtandi, in South Africa. Eurolab and its attorneys established that the patent was invalid. “As a result ...